Results 101 to 110 of about 29,030 (239)

Peripheral accumulation of newly produced T and B lymphocytes in natalizumab-treated multiple sclerosis patients [PDF]

, 2012
The anti-α4 monoclonal antibody natalizumab inhibits lymphocyte extravasation into the central nervous system and increases peripheral T and B lymphocytes in multiple sclerosis patients.
Alessandra Sottini, Bielekova, Cinzia Zanotti, Crowley, del Pilar Martin, Emirena Garrafa, Fabio Torri, Federico Serana, Fletcher, Gorelik, Hug, Ifergan, Kivisäkk, Kogan, Krumbholz, Laplaud, Lee, Luigi Caimi, Luisa Imberti, Lutterotti, Marco Chiarini, Muraro, Niino, Pittet, Planas, Polman, Putzki, Ruggero Capra, Ryan, Sarah Rasia, Sawada, Schwab, Serana, Skarica, Sottini, Sottini, Stüve, Takada, van Zelm, Wipfler, Ye, Zanotti, Zohren   +42 more
core   +1 more source

Ocrelizumab‐induced colitis: VigiBase disproportionality analysis, case reports and literature review

British Journal of Clinical Pharmacology, EarlyView.
Aims Ocrelizumab is a humanized anti‐CD20 monoclonal antibody used in multiple sclerosis. Since its commercialization, several cases of ocrelizumab‐induced colitis have been reported in the scientific literature. Methods To explore the potential association of ocrelizumab with colitis as an adverse drug reaction (ADR), we conducted a descriptive and ...
Audrey Fresse, Christophe Hommel, Nadine Petitpain, Philippe Kerschen   +3 more
wiley   +1 more source

Extended interval dosing of natalizumab: a two-center, 7-year experience

Therapeutic Advances in Neurological Disorders, 2014
Background: The enthusiasm for natalizumab, a highly efficacious agent in the treatment of multiple sclerosis (MS), has been tempered by the risks of progressive multifocal leukoencephalopathy associated with its use, and strategies to minimize those ...
Roberto Bomprezzi, Siddharama Pawate
doaj   +1 more source

Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group [PDF]

, 2015
The use of natalizumab for highly active relapsing-remitting multiple sclerosis (MS) is influenced by the occurrence of progressive multifocal leukoencephalopathy (PML).
Craner, M, Guadagno, J, Kapoor, R, Mazibrada, G, McGuigan, C, Molyneux, P, Nicholas, R, Palace, J, Pearson, OR, Rog, D, Young, CA   +10 more
core   +1 more source

Association of Neurodevelopmental Disorders and Congenital Anomalies With Prenatal Multiple Sclerosis Treatment—Real‐World Historical Cohort Study

Clinical Pharmacology &Therapeutics, EarlyView.
There is a paucity of data regarding the effects of prenatal disease‐modifying therapies (DMTs) for multiple sclerosis (MS), on congenital anomalies in the offspring. Moreover, data on the association with neurodevelopmental disorders are lacking. This is an historical cohort study, within the Israeli Clalit Health Services database (2005–2024) that ...
Bar Rosh, Ofek Levi, Nili Stein, Amir Yahav, Naomi Gronich   +4 more
wiley   +1 more source

Update on Non‐Biological and RNA‐Based Therapeutics in Chronic Inflammatory Diseases: Precision Medicine Through Small Molecules: An EAACI Position Paper

Allergy, EarlyView.
ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...
F. Roth‐Walter, I. M. Adcock, C. Benito‐Villalvilla, R. Bianchini, L. Bjermer, G. Caramori, L. Cari, K. F. Chung, Z. Diamant, I. Eguiluz‐Gracia, E. F. Knol, M. Jesenak, F. Levi‐Schaffer, G. Nocentini, L. O'Mahony, O. Palomares, F. Redegeld, M. Sokolowska, B. Van Esch, M. Zurlo, C. Stellato   +20 more
wiley   +1 more source

Lesion Location and Functional Connections Reveal Cognitive Impairment Networks in Multiple Sclerosis

Annals of Clinical and Translational Neurology, Volume 13, Issue 2, Page 242-255, February 2026.
ABSTRACT Objective Cognitive impairment, fatigue, and depression are common in multiple sclerosis (MS), potentially due to disruption of regional functional connectivity caused by white matter (WM) lesions. We explored whether WM lesions functionally connected to specific brain regions contribute to these MS‐related manifestations.
Alessandro Franceschini, Paolo Preziosa, Paola Valsasina, Damiano Mistri, Monica Margoni, Federica Esposito, Massimo Filippi, Maria A. Rocca   +7 more
wiley   +1 more source

Consenso español actualizado sobre el uso del natalizumab (Tysabri®)-2013

Neurología, 2015
Resumen: Introducción: Natalizumab es un tratamiento que ha demostrado ser muy eficaz en los ensayos clínicos y muy efectivo en la práctica clínica en los pacientes con esclerosis múltiple recurrente-remitente, en cuanto a la reducción del número de ...
O. Fernández, J.A. García-Merino, R. Arroyo, J.C. Álvarez-Cermeño, G. Izquierdo, A. Saiz, J. Olascoaga, A. Rodríguez-Antigüedad, J.M. Prieto, C. Oreja-Guevara, M.A. Hernández, E. Moral, J. Meca, X. Montalbán   +13 more
doaj   +1 more source

Switching multiple sclerosis patients with breakthrough disease to second-line therapy. [PDF]

PLoS ONE, 2011
BACKGROUND: Multiple sclerosis (MS) patients with breakthrough disease on immunomodulatory drugs are frequently offered to switch to natalizumab or immunosuppressants. The effect of natalizumab monotherapy in patients with breakthrough disease is unknown.
Tamara Castillo-Trivino, Ellen M Mowry, Alberto Gajofatto, Dorothee Chabas, Elizabeth Crabtree-Hartman, Bruce A Cree, Douglas S Goodin, Ari J Green, Darin T Okuda, Daniel Pelletier, Scott S Zamvil, Eric Vittinghoff, Emmanuelle Waubant   +12 more
doaj   +1 more source

A decade of natalizumab and PML: Has there been a tacit transfer of risk acceptance? [PDF]

, 2016
The interplay between each of the stakeholder's responsibilities and desires clearly has resulted in continued widespread use of natalizumab with substantial risks and an ongoing quest for better risk mitigation.
Clifford, DB, Major, EO, Yousry, TA
core   +1 more source